Navigation Links
Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
Date:3/12/2013

NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol.  Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat.  Additional terms were not disclosed. 

The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins.  It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.  The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.

"There is remarkable synergy between our research and Topokine's innovative products.  I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.

"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO.  "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.  XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors.  XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About the University of Bristol

The University of Bristol is consistently ranked among the leaders in UK higher education.  Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff.  Places at Bristol are among the most highly sought after of all UK universities.  The University was founded in 1876 and was granted its Royal Charter in 1909.  It was the first university in England to admit women on the same basis as men.  It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England.  Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. Shire Acquires Premacure AB
4. BD Acquires Cato Software Solutions
5. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
6. Dynamic Healthcare Services Acquires the operating assets of APO2, a Provider of Home Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
7. PRA Acquires ClinStar
8. Endexx Acquires Medical Marijuana Management Technology
9. DSI Renal Acquires New Smyrna Beach Artificial Kidney Center
10. Henry Schein Acquires The Maddox Practice Group
11. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):